<?xml version="1.0" encoding="utf-8"?><api:response xmlns:api="http://www.symplectic.co.uk/publications/api"><api:version uri="https://mypublications.shef.ac.uk/" elements-version="6.15.0.3976" schema-version="6.13" product-name="myPublications"/><api:request href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/1143"/><api:result><api:object category="publication" id="1143" last-affected-when="2024-02-18T05:19:43.293+00:00" last-modified-when="2024-02-18T05:19:43.293+00:00" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/1143" created-when="2010-05-17T13:47:32.313+01:00" type-id="5" type-display-name="Journal article" type="journal-article"><api:privacy-level>Public</api:privacy-level><api:privacy-level-locked>false</api:privacy-level-locked><api:ever-approved>true</api:ever-approved><api:reporting-date-1>2000-11-20</api:reporting-date-1><api:allow-type-switching>true</api:allow-type-switching><api:records><api:record format="native" id="2451704" source-id="13" source-name="crossref" source-display-name="Crossref" id-at-source="10.1002/1097-0142(20000615)88:12+&lt;3059::aid-cncr24&gt;3.0.co;2-h" last-modified-when="2022-09-11T03:22:55.157+01:00"><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>Robert E</api:first-names><api:separate-first-names><api:first-name>Robert</api:first-name><api:first-name>E</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1002/1097-0142(20000615)88:12+&lt;3059::aid-cncr24&gt;3.0.co;2-h</api:text><api:links><api:link type="doi" href="http://doi.org/10.1002/1097-0142(20000615)88:12+&lt;3059::aid-cncr24&gt;3.0.co;2-h"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1002/1097-0142(20000615)88:12+&lt;3059::aid-cncr24&gt;3.0.co;2-h"/></api:links></api:field><api:field name="eissn" type="text" display-name="eISSN"><api:text>1097-0142</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973688"/></api:links></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0008-543X</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973688"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>S12</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Cancer</api:text></api:field><api:field name="language" type="text" display-name="Language"><api:text>en</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>3059</api:begin-page><api:end-page>3064</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:day>15</api:day><api:month>6</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Wiley</api:text></api:field><api:field name="publisher-url" type="text" display-name="Link 2"><api:text>http://dx.doi.org/10.1002/1097-0142(20000615)88:12+%3C3059::aid-cncr24%3E3.0.co;2-h</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>1</api:day><api:month>7</api:month><api:year>2021</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>High dose chemotherapy</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>88</api:text></api:field></api:native></api:record><api:record format="native" id="3522761" source-id="7" source-name="scopus" source-display-name="Scopus" id-at-source="2-s2.0-0034659930" suspected-deleted-at-source="true" last-modified-when="2024-04-16T18:44:46.253+01:00"><api:citation-count>4</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>BACKGROUND. High dose chemotherapy (HDC) with hematopoietic stem cell support is an increasingly important strategy in the management of advanced cancer. Early Phase II studies and the development of peripheral blood stem cell support to enable safe and tolerable myeloablative chemotherapy has resulted in its controversial and widespread use in the management of breast carcinoma. Recently, several randomized trials of both advanced breast carcinoma and the adjuvant setting have been reported. METHODS. The technical developments in HDC and results from the randomized clinical trials reported to date were reviewed. RESULTS. Three randomized trials of advanced breast carcinoma and five of high risk adjuvant patients were identified. Only two relatively small trials from South Africa have so far shown an advantage for high dose chemotherapy, and the validity of these trials has recently been seriously challenged. A Scandinavian adjuvant trial showed no advantage for HDC when compared with maximum nonablative doses supported with granulocyte- colony stimulating factor (G-CSF). Four trials were too small to detect clinically realistic differences in outcome whereas the other large adjuvant trial was reported prematurely and the results in the HDC arm were dominated by high procedure-related mortality. CONCLUSIONS. It is difficult to make specific treatment recommendations based on the conclusions from the currently available data. The 1999 American Society of Clinical Oncology reports were inconsistent and in some cases were presented before the results were sufficiently mature to provide statistically reliable data. However, it is clear that, unlike in leukemia, lymphoma, and multiple myeloma, HDC in breast carcinoma should not be used outside the context of a clinical trial. The mature results of the ongoing trials are eagerly awaited, whereas the use of immediate as opposed to consolidation high dose treatment, tandem transplants, and developments in immunologic and genetic manipulation of the graft merit further evaluation. (C) 2000 American Cancer Society.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7403206142</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1002/1097-0142(20000615)88:12+&lt;3059::aid-cncr24&gt;3.0.co;2-h</api:text><api:links><api:link type="doi" href="http://doi.org/10.1002/1097-0142(20000615)88:12+&lt;3059::aid-cncr24&gt;3.0.co;2-h"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1002/1097-0142(20000615)88:12+&lt;3059::aid-cncr24&gt;3.0.co;2-h"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10898352</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0008-543X</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973688"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>12 SUPPL.</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Cancer</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>3059</api:begin-page><api:end-page>3064</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:day>15</api:day><api:month>6</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>High dose chemotherapy: Rationale and results in breast carcinoma</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Conference Proceeding</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>88</api:text></api:field></api:native></api:record><api:record format="native" id="1143" source-id="2" source-name="pubmed" source-display-name="PubMed" id-at-source="10898352" last-modified-when="2020-04-29T00:35:38.607+01:00"><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>BACKGROUND: High dose chemotherapy (HDC) with hematopoietic stem cell support is an increasingly important strategy in the management of advanced cancer. Early Phase II studies and the development of peripheral blood stem cell support to enable safe and tolerable myeloablative chemotherapy has resulted in its controversial and widespread use in the management of breast carcinoma. Recently, several randomized trials of both advanced breast carcinoma and the adjuvant setting have been reported. METHODS: The technical developments in HDC and results from the randomized clinical trials reported to date were reviewed. RESULTS: Three randomized trials of advanced breast carcinoma and five of high risk adjuvant patients were identified. Only two relatively small trials from South Africa have so far shown an advantage for high dose chemotherapy, and the validity of these trials has recently been seriously challenged. A Scandinavian adjuvant trial showed no advantage for HDC when compared with maximum nonablative doses supported with granulocyte-colony stimulating factor (G-CSF). Four trials were too small to detect clinically realistic differences in outcome, whereas the other large adjuvant trial was reported prematurely and the results in the HDC arm were dominated by high procedure-related mortality. CONCLUSIONS: It is difficult to make specific treatment recommendations based on the conclusions from the currently available data. The 1999 American Society of Clinical Oncology reports were inconsistent and in some cases were presented before the results were sufficiently mature to provide statistically reliable data. However, it is clear that, unlike in leukemia, lymphoma, and multiple myeloma, HDC in breast carcinoma should not be used outside the context of a clinical trial. The mature results of the ongoing trials are eagerly awaited, whereas the use of immediate as opposed to consolidation high dose treatment, tandem transplants, and developments in immunologic and genetic manipulation of the graft merit further evaluation.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="full">Yorkshire Cancer Research, Department of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield, England.</api:line></api:address></api:addresses></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.ncbi.nlm.nih.gov/pubmed/10898352</api:text></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1002/1097-0142(20000615)88:12+&lt;3059::aid-cncr24&gt;3.0.co;2-h</api:text><api:links><api:link type="doi" href="http://doi.org/10.1002/1097-0142(20000615)88:12+&lt;3059::aid-cncr24&gt;3.0.co;2-h"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1002/1097-0142(20000615)88:12+&lt;3059::aid-cncr24&gt;3.0.co;2-h"/></api:links></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0008-543X</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973688"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>12 Suppl</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Cancer</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Breast Neoplasms</api:keyword><api:keyword scheme="mesh">Female</api:keyword><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Randomized Controlled Trials as Topic</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="location" type="text" display-name="Country"><api:text>United States</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>3059</api:begin-page><api:end-page>3064</api:end-page></api:pagination></api:field><api:field name="pii" type="text" display-name="PII"><api:text>10.1002/1097-0142(20000615)88:12+&lt;3059::AID-CNCR24&gt;3.0.CO;2-H</api:text></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:day>15</api:day><api:month>6</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-made-public-at-source-date" type="date" display-name="Record made publicly available"><api:date><api:day>27</api:day><api:month>7</api:month><api:year>2000</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>High dose chemotherapy: rationale and results in breast carcinoma.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Journal Article</api:item><api:item>Review</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>88</api:text></api:field></api:native></api:record><api:record format="native" id="882258" source-id="18" source-name="epmc" source-display-name="Europe PubMed Central" id-at-source="MED:10898352" last-modified-when="2021-01-19T17:57:11.647+00:00"><api:citation-count>2</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>&lt;h4&gt;Background&lt;/h4&gt;High dose chemotherapy (HDC) with hematopoietic stem cell support is an increasingly important strategy in the management of advanced cancer. Early Phase II studies and the development of peripheral blood stem cell support to enable safe and tolerable myeloablative chemotherapy has resulted in its controversial and widespread use in the management of breast carcinoma. Recently, several randomized trials of both advanced breast carcinoma and the adjuvant setting have been reported.&lt;h4&gt;Methods&lt;/h4&gt;The technical developments in HDC and results from the randomized clinical trials reported to date were reviewed.&lt;h4&gt;Results&lt;/h4&gt;Three randomized trials of advanced breast carcinoma and five of high risk adjuvant patients were identified. Only two relatively small trials from South Africa have so far shown an advantage for high dose chemotherapy, and the validity of these trials has recently been seriously challenged. A Scandinavian adjuvant trial showed no advantage for HDC when compared with maximum nonablative doses supported with granulocyte-colony stimulating factor (G-CSF). Four trials were too small to detect clinically realistic differences in outcome, whereas the other large adjuvant trial was reported prematurely and the results in the HDC arm were dominated by high procedure-related mortality.&lt;h4&gt;Conclusions&lt;/h4&gt;It is difficult to make specific treatment recommendations based on the conclusions from the currently available data. The 1999 American Society of Clinical Oncology reports were inconsistent and in some cases were presented before the results were sufficiently mature to provide statistically reliable data. However, it is clear that, unlike in leukemia, lymphoma, and multiple myeloma, HDC in breast carcinoma should not be used outside the context of a clinical trial. The mature results of the ongoing trials are eagerly awaited, whereas the use of immediate as opposed to consolidation high dose treatment, tandem transplants, and developments in immunologic and genetic manipulation of the graft merit further evaluation.</api:text></api:field><api:field name="addresses" type="address-list" display-name="Addresses"><api:addresses><api:address iso-country-code="GB"><api:line type="full">Yorkshire Cancer Research, Department of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield, England.</api:line></api:address></api:addresses></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1002/1097-0142(20000615)88:12+&lt;3059::aid-cncr24&gt;3.0.co;2-h</api:text><api:links><api:link type="doi" href="http://doi.org/10.1002/1097-0142(20000615)88:12+&lt;3059::aid-cncr24&gt;3.0.co;2-h"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1002/1097-0142(20000615)88:12+&lt;3059::aid-cncr24&gt;3.0.co;2-h"/></api:links></api:field><api:field name="eissn" type="text" display-name="eISSN"><api:text>1097-0142</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973688"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10898352</api:identifier></api:identifiers></api:field><api:field name="is-open-access" type="boolean" display-name="Open access"><api:boolean>false</api:boolean></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0008-543X</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973688"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>12 Suppl</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Cancer</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Breast Neoplasms</api:keyword><api:keyword scheme="mesh">Female</api:keyword><api:keyword scheme="mesh">Randomized Controlled Trials as Topic</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="medium" type="text" display-name="Medium"><api:text>Print</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>3059</api:begin-page><api:end-page>3064</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>6</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>18</api:day><api:month>7</api:month><api:year>2000</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>High dose chemotherapy: rationale and results in breast carcinoma.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Review</api:item><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>88</api:text></api:field></api:native></api:record><api:record format="native" id="3522965" source-id="10" source-name="dimensions" source-display-name="Dimensions" id-at-source="pub.1033316758" last-modified-when="2024-02-18T05:19:43.3+00:00"><api:citation-count>4</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>Robert E</api:first-names><api:separate-first-names><api:first-name>Robert</api:first-name><api:first-name>E</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.014331105607.96</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1002/1097-0142(20000615)88:12+&lt;3059::aid-cncr24&gt;3.0.co;2-h</api:text><api:links><api:link type="doi" href="http://doi.org/10.1002/1097-0142(20000615)88:12+&lt;3059::aid-cncr24&gt;3.0.co;2-h"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1002/1097-0142(20000615)88:12+&lt;3059::aid-cncr24&gt;3.0.co;2-h"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10898352</api:identifier></api:identifiers></api:field><api:field name="field-citation-ratio" type="decimal" display-name="Field citation ratio"><api:decimal>0.42</api:decimal></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0008-543X</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973688"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>S12</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Cancer</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="for-2020">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="for-2020">3211 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="rcdc">Transplantation</api:keyword><api:keyword scheme="rcdc">Cancer</api:keyword><api:keyword scheme="rcdc">Clinical Trials and Supportive Activities</api:keyword><api:keyword scheme="rcdc">Breast Cancer</api:keyword><api:keyword scheme="rcdc">Clinical Research</api:keyword><api:keyword scheme="rcdc">Rare Diseases</api:keyword><api:keyword scheme="rcdc">Hematology</api:keyword><api:keyword scheme="hrcs-rac">6.1 Pharmaceuticals</api:keyword><api:keyword scheme="hrcs-rac">6 Evaluation of treatments and therapeutic interventions</api:keyword><api:keyword scheme="hrcs-hc">Cancer</api:keyword><api:keyword scheme="mesh">Breast Neoplasms</api:keyword><api:keyword scheme="mesh">Female</api:keyword><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Randomized Controlled Trials as Topic</api:keyword></api:keywords></api:field><api:field name="online-publication-date" type="date" display-name="Online publication date"><api:date><api:day>20</api:day><api:month>11</api:month><api:year>2000</api:year></api:date></api:field><api:field name="open-access-status" type="text" display-name="Open access status"><api:text>Bronze OA</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>3059</api:begin-page><api:end-page>3064</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:day>15</api:day><api:month>6</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Wiley</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>31</api:day><api:month>8</api:month><api:year>2017</api:year></api:date></api:field><api:field name="relative-citation-ratio" type="decimal" display-name="Relative citation ratio"><api:decimal>0.03</api:decimal></api:field><api:field name="title" type="text" display-name="Title"><api:text>High dose chemotherapy</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>88</api:text></api:field></api:native></api:record><api:record format="native" id="3098847" source-id="10" source-name="dimensions" source-display-name="Dimensions" id-at-source="pub.1074669160" suspected-deleted-at-source="true" last-modified-when="2024-04-14T19:13:51.68+01:00"><api:citation-count>1</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.014331105607.96</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10898352</api:identifier></api:identifiers></api:field><api:field name="field-citation-ratio" type="decimal" display-name="Field citation ratio"><api:decimal>0.11</api:decimal></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0008-543X</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973688"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>12 Suppl</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Cancer</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="rcdc">Hematology</api:keyword><api:keyword scheme="rcdc">Transplantation</api:keyword><api:keyword scheme="rcdc">Cancer</api:keyword><api:keyword scheme="rcdc">Breast Cancer</api:keyword><api:keyword scheme="rcdc">Rare Diseases</api:keyword><api:keyword scheme="rcdc">Clinical Research</api:keyword><api:keyword scheme="rcdc">Clinical Trials and Supportive Activities</api:keyword><api:keyword scheme="hrcs-rac">6.1 Pharmaceuticals</api:keyword><api:keyword scheme="hrcs-rac">6 Evaluation of treatments and therapeutic interventions</api:keyword><api:keyword scheme="hrcs-hc">Cancer</api:keyword><api:keyword scheme="mesh">Breast Neoplasms</api:keyword><api:keyword scheme="mesh">Female</api:keyword><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Randomized Controlled Trials as Topic</api:keyword></api:keywords></api:field><api:field name="open-access-status" type="text" display-name="Open access status"><api:text>Closed Access</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>3059</api:begin-page><api:end-page>3064</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:day>15</api:day><api:month>6</api:month><api:year>2000</api:year></api:date></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>31</api:day><api:month>8</api:month><api:year>2017</api:year></api:date></api:field><api:field name="relative-citation-ratio" type="decimal" display-name="Relative citation ratio"><api:decimal>0.03</api:decimal></api:field><api:field name="title" type="text" display-name="Title"><api:text>High dose chemotherapy: rationale and results in breast carcinoma.</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>88</api:text></api:field></api:native></api:record></api:records><api:fields/><api:all-labels type="keyword-list"><api:keywords><api:keyword scheme="mesh" origin="record-data" source="pubmed">Breast Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Female</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Randomized Controlled Trials as Topic</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Breast Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Female</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Randomized Controlled Trials as Topic</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">3211 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Transplantation</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Cancer</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Clinical Trials and Supportive Activities</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Breast Cancer</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Clinical Research</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Rare Diseases</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Hematology</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">6.1 Pharmaceuticals</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">6 Evaluation of treatments and therapeutic interventions</api:keyword><api:keyword scheme="hrcs-hc" origin="record-data" source="dimensions">Cancer</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Breast Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Female</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Randomized Controlled Trials as Topic</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Hematology</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Transplantation</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Cancer</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Breast Cancer</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Rare Diseases</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Clinical Research</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Clinical Trials and Supportive Activities</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">6.1 Pharmaceuticals</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">6 Evaluation of treatments and therapeutic interventions</api:keyword><api:keyword scheme="hrcs-hc" origin="record-data" source="dimensions">Cancer</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Breast Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Female</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Randomized Controlled Trials as Topic</api:keyword><api:keyword scheme="for" origin="issn-inferred">1112 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="for" origin="issn-inferred">1117 Public Health and Health Services</api:keyword><api:keyword scheme="science-metrix" origin="issn-inferred">Oncology &amp; Carcinogenesis</api:keyword><api:keyword scheme="for-2020" origin="issn-inferred">3211 Oncology and carcinogenesis</api:keyword><api:keyword scheme="for-2020" origin="issn-inferred">4206 Public health</api:keyword></api:keywords></api:all-labels><api:journal issn="0008-543X" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973688" title="Cancer"><api:records><api:record source-name="summary"><api:title>Cancer</api:title></api:record></api:records></api:journal><api:relationships href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/1143/relationships"/></api:object></api:result></api:response>